Gemcitabine for Marginal Zone Lymphoma

This study has been terminated.

(poor accrual and response less than expected on interim analysis)

Sponsor:

Collaborator:

Eli Lilly and Company

Information provided by (Responsible Party):

Cheolwon Suh, Asan Medical Center

ClinicalTrials.gov Identifier:

NCT00337259

First received: June 14, 2006

Last updated: February 13, 2016

Last verified: February 2016

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	March 2009
Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)